On February 18, 2026, President Trump signed an executive order invoking the Defense Production Act to boost domestic production of glyphosate-based herbicides — the active ingredient in Roundup, which has been linked to a 41% higher cancer risk and has triggered over 125,000 lawsuits from people diagnosed with non-Hodgkin lymphoma. The order, titled “Promoting the National Defense by Ensuring an Adequate Supply of Elemental Phosphorus and Glyphosate-Based Herbicides,” declares glyphosate “central to American economic and national security” and directs USDA Secretary Brooke Rollins to prioritize all materials, services, and facilities necessary to keep supply flowing. It also includes a liability shield provision drawn from the Defense Production Act that could give manufacturers another legal defense against cancer claims. The timing alone raised eyebrows.
Just one day before the executive order, Bayer proposed a $7.25 billion class action settlement to resolve tens of thousands of Roundup cancer lawsuits. The convergence of a massive corporate settlement and a presidential order designed to protect the sole domestic producer of glyphosate drew immediate backlash from Make America Healthy Again activists, environmental groups, and plaintiffs’ attorneys. This article breaks down what the executive order actually does, how it interacts with ongoing litigation, what it means for the proposed Bayer settlement, and why even RFK Jr. — a longtime glyphosate opponent — ended up defending it.
Table of Contents
- What Does Trump’s Executive Order on Roundup’s Cancer-Causing Chemical Actually Do?
- The Bayer Settlement and Suspicious Timing
- What the Science Says About Glyphosate and Cancer
- How the Liability Shield Works — and What It Does Not Do
- MAHA Backlash and the RFK Jr. Problem
- Environmental and Public Health Groups Sound the Alarm
- What Comes Next — The Supreme Court and Beyond
- Conclusion
- Frequently Asked Questions
What Does Trump’s Executive Order on Roundup’s Cancer-Causing Chemical Actually Do?
The executive order invokes the Defense Production Act, a Cold War-era law originally designed to ensure the military had enough materials during wartime. trump‘s order repurposes it to frame glyphosate-based herbicides and elemental phosphorus (a key ingredient in their manufacture) as matters of national defense and food-supply security. Currently, there is only one domestic producer of both elemental phosphorus and glyphosate-based herbicides in the United States, which the administration argues makes the supply chain dangerously vulnerable. The order directs USDA Secretary Brooke Rollins to “determine the proper nationwide priorities and allocation of all the materials, services, and facilities necessary” to maintain and expand domestic glyphosate production. It also instructs Rollins to ensure that any regulatory actions do not place the “corporate viability” of any domestic producer at risk — language that effectively tells federal agencies to go easy on the industry.
For comparison, previous uses of the Defense Production Act under both Trump and Biden targeted things like ventilators during COVID-19, semiconductor manufacturing, and critical minerals for electric vehicles. Applying it to a weedkiller is a significant departure. Perhaps the most controversial element is the order’s invocation of the DPA’s built-in liability shield, which states: “No person shall be held liable for damages or penalties for any act or failure to act resulting directly or indirectly from. compliance.” While that language exists in the statute, legal experts have been quick to point out what it does not do — it does not automatically dismiss pending cases, overturn jury verdicts, or rewrite product liability law. It does, however, hand corporate defense teams another argument to deploy in courtrooms.
The Bayer Settlement and Suspicious Timing
One day before the executive order was signed, on February 17, 2026, Bayer proposed a $7.25 billion class action settlement to resolve most of the remaining Roundup cancer lawsuits. The settlement is designed to address roughly 65,000 outstanding claims from the more than 125,000 plaintiffs who have filed suit since 2015. Average awards under the proposed deal range from $10,000 to $165,000, funded through capped annual payments over up to 21 years. To be eligible, claimants must have been exposed to Roundup and diagnosed with non-Hodgkin lymphoma before February 17, 2026, or within 16 years after final court approval of the settlement. A preliminary approval hearing was scheduled for March 4, 2026.
However, there is significant pushback: lawyers representing approximately 20,000 plaintiffs have raised objections, arguing the settlement amounts are inadequate given the severity of the injuries and the strength of the evidence against Bayer. The back-to-back timing of the settlement proposal and the executive order has fueled suspicion among plaintiffs’ attorneys and health advocates. While there is no public evidence of direct coordination between Bayer and the White House, the optics are difficult to ignore. The executive order’s liability shield provision and its directive to protect the “corporate viability” of domestic glyphosate producers could strengthen Bayer’s legal position in negotiations and in court. If the settlement faces judicial scrutiny, the existence of a presidential order framing glyphosate as essential to national security gives the company a powerful narrative tool — even if the legal effect of that order on individual tort claims remains uncertain.
What the Science Says About Glyphosate and Cancer
The health evidence against glyphosate has been building for over a decade. In 2015, the World Health Organization’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans,” a designation that became the cornerstone of tens of thousands of lawsuits. More recent research has linked glyphosate exposure to a 41% higher cancer risk, specifically for non-Hodgkin lymphoma. Multiple juries, after reviewing the evidence in individual trials, have found Roundup responsible for causing plaintiffs’ cancers and have awarded substantial damages. Bayer has consistently maintained that glyphosate is safe when used as directed, pointing to regulatory assessments from agencies like the EPA that have not classified it as a carcinogen. This split between the WHO’s IARC finding and the EPA’s position is at the heart of a legal question heading to the U.S.
Supreme Court in April 2026: whether EPA approval of Roundup preempts state-court cancer claims. If the Supreme Court sides with Bayer, it could effectively shut down future state-level lawsuits regardless of the scientific evidence, because plaintiffs would be barred from arguing that Roundup should have carried stronger cancer warnings than what the EPA required. The executive order notably does not engage with the cancer science at all. It does not reference the IARC classification, the jury verdicts, or the epidemiological research. Instead, it treats glyphosate purely as an agricultural input essential to food security. This framing is deliberate — acknowledging the health risks would undermine the order’s stated purpose of boosting production.
How the Liability Shield Works — and What It Does Not Do
The DPA liability shield cited in the executive order is real, but its practical impact on Roundup litigation is far from settled. The provision protects individuals and companies from liability for actions taken in compliance with a DPA order. In theory, a glyphosate manufacturer could argue that producing Roundup at the government’s direction shields it from cancer lawsuits. In practice, legal experts have noted significant limitations. The shield likely applies prospectively — to actions taken after the order — not retroactively to the decades of Roundup sales that generated existing lawsuits.
It also protects actions taken “in compliance” with the order, which means manufacturing and distributing glyphosate, not necessarily the failure to warn consumers about cancer risks or the marketing decisions that plaintiffs have challenged. According to analysis from Drugwatch and the American Chemical Society’s Chemical & Engineering News, the order introduces another potential defense argument but does not fundamentally change the legal landscape for pending cases. The tradeoff for Bayer and other manufacturers is strategic. The executive order gives them a talking point — the President of the United States has declared their product essential to national security — but it does not give them a get-out-of-court-free card. Plaintiffs’ attorneys can and will argue that the order is irrelevant to the core question of whether Roundup causes cancer and whether the company failed to warn users. The real legal battleground remains the Supreme Court case in April 2026, which could deliver a far more definitive ruling on preemption than any executive order.
MAHA Backlash and the RFK Jr. Problem
The executive order drew sharp criticism from Make America Healthy Again activists, the health-focused wing of Trump’s base that had rallied around promises to reduce Americans’ exposure to toxic chemicals, pesticides, and processed food additives. Critics called the glyphosate order “the exact opposite of what MAHA voters were promised,” and the backlash was swift on social media and in conservative health advocacy circles. The most awkward figure in this controversy is Robert F. Kennedy Jr., now serving as Secretary of Health and Human Services. RFK Jr. built a significant part of his public profile on opposing pesticides in general and glyphosate in particular.
As an attorney, he helped win a Roundup cancer lawsuit in 2018 — one of the landmark verdicts that forced Bayer to the settlement table. Despite this history, Kennedy publicly defended Trump’s executive order after it was signed, a reversal that alienated many of his own supporters and raised questions about whether his position as HHS Secretary had effectively neutralized one of the most prominent anti-glyphosate voices in American public life. The political risk here extends beyond Kennedy personally. MAHA voters were a meaningful constituency in the 2024 election, and their enthusiasm was driven by a belief that the Trump administration would take on the chemical and pharmaceutical industries. An executive order that boosts production of a probable carcinogen while shielding its manufacturer from lawsuits is a direct contradiction of that promise. Whether this translates into electoral consequences depends on how loudly MAHA activists continue to push back and whether the administration offers any compensating action on food safety or chemical regulation.
Environmental and Public Health Groups Sound the Alarm
The Waterkeeper Alliance, a national clean water advocacy organization, issued a statement criticizing the executive order alongside provisions of the 2026 Farm Bill as twin threats to clean water and public health. Glyphosate runoff from agricultural use has been detected in waterways, drinking water sources, and rainwater across the country.
Boosting domestic production could increase the total volume of glyphosate entering the environment, particularly if the order’s directive to protect the “corporate viability” of producers translates into relaxed environmental oversight. Environmental groups have also noted the irony of invoking the Defense Production Act — a law meant to protect national security — for a chemical that public health researchers have linked to cancer. The concern is not just about the immediate legal and health implications, but about the precedent: if the DPA can be used to shield pesticide manufacturers, it could theoretically be used to protect any industry that frames its product as essential to the food supply or the economy.
What Comes Next — The Supreme Court and Beyond
The most consequential development in the Roundup saga may not be the executive order at all, but the U.S. Supreme Court arguments scheduled for April 2026. The central question is whether EPA approval of a pesticide label preempts state-court failure-to-warn claims. If the Court rules in Bayer’s favor, it would effectively end the ability of individual plaintiffs to sue over Roundup’s cancer risks in state courts, regardless of how strong the scientific evidence becomes.
Meanwhile, the proposed $7.25 billion settlement faces its own uncertain path. With lawyers for roughly 20,000 plaintiffs pushing back and a preliminary approval hearing on the calendar, the deal is far from finalized. If the settlement collapses and the Supreme Court does not grant broad preemption, tens of thousands of cases could proceed to trial — executive order or not. For the estimated 65,000 claimants waiting for resolution, the next several months will determine whether they receive compensation through the settlement, fight on in court, or find their claims preempted entirely. The executive order adds noise to this process, but the signal will come from the courts.
Conclusion
Trump’s executive order on glyphosate is a remarkable convergence of industrial policy, tort litigation, and political contradiction. It uses a national defense law to boost production of a chemical that the World Health Organization has classified as a probable carcinogen, includes a liability shield that could benefit the sole domestic producer in ongoing cancer lawsuits, and was signed one day after that producer’s parent company proposed a $7.25 billion settlement. Whether the order has meaningful legal teeth or is primarily a symbolic gesture remains an open question that courts — not the White House — will ultimately answer.
For consumers, plaintiffs, and MAHA activists, the takeaway is that the legal and political fight over Roundup is far from over. The Supreme Court’s April 2026 hearing on preemption, the fate of the proposed Bayer settlement, and the practical implementation of the executive order will all shape whether glyphosate victims receive justice or whether the chemical industry emerges with stronger protections than ever. Paying attention to these developments — and to the actions of officials like RFK Jr. who have reversed longstanding positions — is essential for anyone affected by Roundup exposure or concerned about the government’s role in regulating known health risks.
Frequently Asked Questions
Does Trump’s executive order make it legal for Roundup to cause cancer without consequences?
No. The order does not change product liability law, dismiss pending lawsuits, or overturn jury verdicts. It includes a Defense Production Act liability shield that could give manufacturers an additional defense argument, but legal experts say its practical impact on existing Roundup cancer cases is limited.
Who is eligible for the proposed $7.25 billion Bayer settlement?
Anyone exposed to Roundup who was diagnosed with non-Hodgkin lymphoma before February 17, 2026, or within 16 years after final court approval of the settlement. Average awards range from $10,000 to $165,000.
Did RFK Jr. support or oppose the glyphosate executive order?
Despite his long history of opposing glyphosate — including helping win a Roundup cancer lawsuit in 2018 — RFK Jr. publicly defended Trump’s executive order after it was signed, drawing criticism from his own supporters and MAHA activists.
What happens if the Supreme Court rules in Bayer’s favor on preemption?
If the Court rules that EPA approval of Roundup preempts state-court cancer claims, it could effectively end the ability of individual plaintiffs to sue over Roundup’s cancer risks in state courts, which would be a far more significant development than the executive order.
How much has Bayer already paid in Roundup settlements?
Bayer previously agreed to pay approximately $10 billion in 2020 to resolve earlier rounds of litigation. The new proposed $7.25 billion settlement would address most of the remaining 65,000 claims from over 125,000 total plaintiffs since 2015.
Is glyphosate officially classified as a carcinogen?
The WHO’s International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans” in 2015. However, the U.S. EPA has not classified it as a carcinogen, and this regulatory split is at the center of the Supreme Court case scheduled for April 2026.